Primary Market :
Solvay companies are front runners in psychotropic treatments, gastro-intestinal drugs and enzymes, laxatives and hormone replacement therapy.
Solvay Pharmaceutical’s strategy has made it a leader in a small and carefully selected range of fields. Development is concentrated on indications for which clinical need for treatment is most urgent and where Solvay feels it has an innovative contribution to make.
New drugs developed by Solvay’s researchers, new formulations and licensing agreements will extend the range of treatments available worldwide.
|Pharmaceuticals (not all production indications are offered in all countries)|
|Anti-depressant; treatment of Obsessive Compulsive Disorders||LUVOX
|fluvoxamine (selective serotonin reuptake inhibitor)|
|Treatment of manic depressive disorder||LITHOBID||lithium carbonate s.r.|
|Hormone Replacement Therapies|
Menopausal symptoms, osteoporosis
|Hepatic coma, constipation||BIFITERAL
|Pancreatic deficiencies: especially cystic fibrosis and chronic pancreatis||CREON||lipases, amylases and proteases|
|Irritable bowel syndrom||DUSPATAL
|Inflammatory complaints of the colon||DICETEL||pinaverine|
Geographic breakdown of sales in 1999
(Total sales: EUR 1,349 million)
European Union 44 % Other European Countries 10 % Nafta 38 % Mercosur < 1 % Africa – Middle-East 4% Asia – Pacific (including Japan) 4%